T cell response to human papillomavirus 16 E7 in mice: Comparison of Cr release assay, intracellular IFN-γ production, ELISPOT and tetramer staining

Intervirology

Volumn 45, Issue 4-6, 2002, Pages 290-299

  Michel, Nico ^a   Öhlschläger, Peter ^a   Osen, Wolfram ^a   Freyschmidt, Eva Jasmin ^a   Guthöhrlein, Heidrun ^a   Kaufmann, Andreas M ^b   Müller, Martin ^a   Gissmann, Lutz ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Cr release; DNA immunization; ELISPOT; HPV 16 E7; Intracellular IFN ; Tetramer staining

Indexed keywords

GAMMA INTERFERON; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY DETECTION; CELLULAR IMMUNITY; CHROMIUM RELEASE ASSAY; CONFERENCE PAPER; CONTROLLED STUDY; DNA VECTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRUS;

EID: 0036983428     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067923     Document Type: Conference Paper

References (48)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide (see comments). J Pathol 1999;189:12-19.
3. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC: Immunological analyses of human papillomavirus capsides. Vaccine 2001;19:1783-1793.
4. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group (see comments). J Natl Cancer Inst 1995;87:796-802.
5. Richart RM: Cervical intraepithelial neoplasia. Pathol Annu 1973;8:301-328.
6. Ostor AG: Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993;12:186-192.
7. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH: Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-1869.
8. Konya J, Dillner J: Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001;82:205-238.
9. von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L: Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1998;48:3780-3786.
10. Hohn H, Pilch H, Gunzel S, Neukirch C, Freitag K, Necker A, Maeurer MJ: Human papillomavirus type 3 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. J Virol 2000;74:6632-6636.
11. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R: Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001;91:612-618.
12. Rudolf MP, Man S, Melief CJ, Sette A, Kast WM: Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 2001;7:788s-795s.
13. Ressing ME, de Jong JH, Brandt RM, Drijfhout JW, Benckhuijsen WE, Schreuder GM, Offringa R, Kast WM, Melief CJ: Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol 1999;29:1292-1303.
14. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman A, Anholts JD, Schreuder GM, ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJ: Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-588.
15. Luxton JC, Rowe AJ, Cridland JC, Coletart T, Wilson P, Shepherd PS: Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J Gen Virol 1996;77:1585-1593.
16. Vandebriel RJ, van der Kolk M, Geerse L, Steerenberg PA, Krul MR: A helper T-cell epitope of the E7 protein of human papillomavirus type 16 in BALB/c mice. Virus Res 1995;37:13-22.
17. Sarkar AK, Tortolero-Luna G, Nehete PN, Arlinghaus RB, Mitchell MF, Sastry KJ: Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. Viral Immunol 1995;8:165-174.
18. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154:5934-5943.
19. Kast WM, Brandt RM, Drijfhout JW, Melief CJ: Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993;14:115-120.
20. Tindle RW, Fernando GJ, Sterling JC, Frazer IH: A 'public' T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991;88:5887-5891.
21. Comerford SA, McCance DJ, Dougan G, Tite JP: Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16. J Virol 1991;65:4681-4690.
22. Fernando GJ, Tindle RW, Frazer IH: T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18). Virus Res 1995;36:1-13.
23. Gissmann L, Osen W, Müller M, Jochmus I: Therapeutic vaccines for human papillomaviruses. Intervirology 2001;44:167-175.
24. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, Kast WM: Cervical cancer vaccines: Emerging concepts and developments. J Cell Physiol 2001;186:169-182.
25. Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J: Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 2000;7:1859-1866.
26. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC: Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000;270:146-161.
27. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, Chen SL: Recombinant adeno-associated virus expressing human papilloma-virus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000;74:2888-2894.
28. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC: Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996;14:1485-1494.
29. Tindle R: Vaccines for Human Papillomavirus Infection and Anogenital Disease. Austin, Landes, 1999.
30. Breitburd F, Coursaget P: Human papillomavirus vaccines. Semin Cancer Biol 1999;9:431-444.
31. Da Silva DM, Velders MP, Rudolf MP, Schiller JT, Kast WM: Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Ther 1999;1:82-88.
32. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
33. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999;354:20-25.
34. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker E: A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3:1-196.
35. Christensen ND, Kreider JW, Shah KV, Rando RF: Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992;73:1261-1267.
36. Schreckenberger C, Sethupathi P, Kanjanahaluethai A, Müller M, Zhou J, Gissmann L, Qiao L: Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine 2000;19:227-233.
37. Leder C, Kleinschmidt JA, Wiethe C, Müller M: Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 2001;75:9201-9209.
38. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-292.
39. Müller M, Zhou J, Reed TD, Rittmüller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L: Chimeric papillomavirus-like particles. Virology 1997;234:93-111.
40. Jochmus I, Schäfer K, Faath S, Müller M, Gissmann L: Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999;30:269-274.
41. Schäfer K, Müller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I: Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999;81:881-888.
42. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D: Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998;72:8220-8229.
43. Osen W, Peiler T, Öhlschläger P, Caldeira S, Faath S, Michel N, Müller M, Tommasino M, Jochmus I, Gissmann L: A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 2001;19:4276-4286.
44. Michel N, Osen W, Gissmann L, Schumacher TNM, Zentgraf H, Müller M: Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002;294:47-59.
45. Ljunggren HG, Kärre K: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-1759.
46. Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, Hammerling GJ, Rammensee HG: Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997;27:2391-2399.
47. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249.
48. Tindle RW, Herd K, Doan T, Bryson G, Leggatt GR, Lambert P, Frazer IH, Street M: Non-specific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. J Virol 2001;75:5985-5997.